Multiple Sclerosis Clinical Trial
— FASTOfficial title:
Evaluation of the Impact of Experimentally Induced Fatigability on Motor and Cognitive Functions. Effect of High Intensity Training on Motor and Cognitive Functions:a Pilot Randomized Controlled Trial
Fatigability is one of the most prevalent disorder in MS followed by walking, balance and cognitive disorders. However, there are few experimental studies on the effects of fatigability on balance and gait hampering the knowledge of causal fatigue-related changes of walking, balance and cognition. Nowadays, instrumented systems such as wearable devices and optoelectronic systems are available and can be used to provide quantitative and objective indexes useful to monitor the changes of gait parameters during a fatiguing performance. (Moreover), instrumented assessment of patients' performances in dual task paradigms can reveal the possible impact of fatigability on cognitive functions. So far, high intensity functional training has been already used in MS to reduce fatigability. However, the true impact of reduced fatigability on walking, balance and cognition has not been assessed after a fatiguing task making impossible to understand the real impact of treatments focusing on fatigability on these functions. Thus, the aims of the present proposal are to assess the: 1) the acute effect of experimentally induced motor fatigability on walking, balance and cognitive functions using an objective instrumented assessment before, during, and after an overground fatiguing walking test. 2) to investigate the effect of high intensity multimodal functional training to improve motor and cognitive disorders.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | March 1, 2025 |
Est. primary completion date | March 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - More than 18 years of age - Clinical diagnosis of Multiple Sclerosis (MS) - Stable disease course without worsening more than 1 EDSS point over the last 3 months, -EDSS between 1.5 and 6 points - Must be able to maintain upright posture without any assistance for 30 seconds - Must be able to release a written informed consent. Exclusion Criteria: - MS relapse within the previous three months; - Unable to comprehend the aims of the study and to follow test instructions; - Diagnosis of major depression (DSM-5); - Severe joint and/or bone disorders interfering with balance and gait (based upon clinical judgment); - Cardiovascular diseases; - Unconfirmed or uncertain diagnosis of MS (McDonald criteria) - Other concomitant neurological disease; - Patients already performing aerobic or walking exercise. |
Country | Name | City | State |
---|---|---|---|
Italy | Fondazione IRCCS Don Carlo Gnocchi | Milan | MI |
Lead Sponsor | Collaborator |
---|---|
Fondazione Don Carlo Gnocchi Onlus | Ente Ospedaliero Ospedali Galliera, Fondazione Italiana Sclerosi Multipla |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Modified Fatigue Impact Scale (MFIS) | Assessment of fatigue with a 21-items questionnaire that ranges from 0 to 36 as maximum score. | Baseline and at 6-8 weeks (after the completion of 16 training sessions) | |
Other | Multiple Sclerosis Walking Scale-12 (MSWS-12) | Assessment of perceived walking ability with a 12-items questionnaire that ranges from a minimum of 12 points to a maximum of 60 points. | Baseline and at 6-8 weeks (after the completion of 16 training sessions) | |
Other | Activities Balance Confidence Scale (ABC) | Assessment of perceived balance with a 16-items questinnaire that ranges from a minimum of 0% to a maximum of 100%. | Baseline and at 6-8 weeks (after the completion of 16 training sessions) | |
Other | Beck Depression Inventory (BDI-II). | Assessment of mood and anxiety with a 21-items questionnaire that ranges from a minimum of 0 points to a maximum of 63 points | Baseline and at 6-8 weeks (after the completion of 16 training sessions) | |
Primary | difference in walking velocity during the fatiguing walking test | difference between velocity at the beginning of the test and velocity at the end of the fatiguability walking test, [m/s] | Baseline and at 6-8 weeks (after the completion of 16 training sessions) | |
Secondary | gait asymmetry and gait regularity | gait asymmetry, gait regularity on the vertical and medio-lateral plane estimated by autocorrelation coefficients during the fatiguability walking test. These variables will be calculated from IMU's data. | Baseline and at 6-8 weeks (after the completion of 16 training sessions) | |
Secondary | Antero-posterior and medio-lateral accelerations in stabilometric tasks | Antero-posterior and medio-lateral accelerations from the IMU placed on the pelvis during a 60 seconds tasks performed with open and closed eyes. | Baseline and at 6-8 weeks (after the completion of 16 training sessions) | |
Secondary | Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS) | BICAMS includes the Symbol Digit Modalities test (SDMT), the California Verbal Learning Test-2 (CVLT2) and the Brief Visuospatial Memory Test-Revised (BVMT-R).
The total scores will be calculated considering the normative scores. The score on the oral SDMT varies from 0 to 110 and must be calculated with respect to years of schooling. The CVLT2 score varies from a minimum of 0 to a maximum of 16 points. The BVMT-R score ranges from a minimum of 0 to a maximum of 36 points. |
Baseline and at 6-8 weeks (after the completion of 16 training sessions) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |